Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Rating Upgraded by Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

A number of other analysts also recently commented on the company. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.86.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $38.93 on Friday. The firm’s 50-day simple moving average is $36.42 and its 200-day simple moving average is $30.49. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $39.79. The firm has a market cap of $2.89 billion, a P/E ratio of 973.49 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Thomas Malley sold 78,233 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the sale, the director owned 12,546 shares of the company’s stock, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eben Tessari sold 138,614 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total value of $4,601,984.80. Following the sale, the chief operating officer owned 49,915 shares in the company, valued at approximately $1,657,178. The trade was a 73.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 905,298 shares of company stock worth $32,343,574. Company insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently modified their holdings of KNSA. Oregon Public Employees Retirement Fund purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $90,000. State of Alaska Department of Revenue purchased a new position in Kiniksa Pharmaceuticals International in the third quarter valued at about $88,000. SG Americas Securities LLC grew its stake in Kiniksa Pharmaceuticals International by 3.7% during the 3rd quarter. SG Americas Securities LLC now owns 139,318 shares of the company’s stock valued at $5,410,000 after purchasing an additional 4,914 shares in the last quarter. Sheets Smith Wealth Management acquired a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $278,000. Finally, Farther Finance Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 582.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after purchasing an additional 1,159 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.